Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated preoperative FOLFOX chemoradiotherapy for locally advanced rectal cancer
ACTRN12610000175077Phase 2Completed
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Apr 2010
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, fluorouracil and folinic acid in rectal adenocarcinoma, sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoint: Tolerability rate. Started Apr 2010; status: completed.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ACTRN12610000175077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000175077.